Showing 2551-2560 of 3223 results for "".
- New Acuvue Campaign Encourages Gen Z to Take a Social Media Breakhttps://modernod.com/news/new-acuvue-campaign-encourages-gen-z-to-take-a-social-media-break/2481606/The Acuvue brand announced the "Where Vision Meets Sight" social media campaign (#MyVisionMySight) that aims to encourage Gen Z to take social media breaks—to not only give their eyes a rest, but also recognize the impact screen time is having in their lives, according t
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac
- Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023https://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-at-arvo-2023/2481541/Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-cryst
- Ocumension Therapeutics Submits a New Drug Application for Zerviate in Chinahttps://modernod.com/news/ocumension-therapeutics-submits-a-new-drug-application-for-zerviate-in-china/2481533/Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) for approval to commercialize Zerviate (cetirizine ophthalmic solution), 0.24%, in China, for ocular itching associated with allergic conjunctivitis. The approval p
- Ocutrx Technologies Acquires Circuit Board Manufacturing Company Spectrum Advanced Manufacturing Technologieshttps://modernod.com/news/ocutrx-technologies-acquires-circuit-board-manufacturing-company-spectrum-advanced-manufacturing-technologies/2481531/Ocutrx Technologies announced it has acquired Spectrum Advanced Manufacturing Technologies, a Colorado-based electronics manufacturing and assembly company. Terms of the deal were not disclosed. With this acquisition, the consolidated Oxutrx_Spectrum company now
- NEI: Extremely Rare Gene Variants Point to a Potential Cause of AMDhttps://modernod.com/news/nei-extremely-rare-gene-variants-point-to-a-potential-cause-of-amd/2481519/A study from the National Eye Institute (NEI) identified rare genetic variants that could point to one of the general mechanisms driving age-related macular degeneration (AMD). The variants generate malformed proteins that alter the stability of the membrane attack complex (MAC), which may drive
- TearRestore’s Thermal Mask & HylaWipe Tea Tree Eyelid Wipes Now Available at Targethttps://modernod.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at Target stores nationwide and at Target.com. The Thermal Mask and Eye Wipe offer alternative options to artificial tears and are designed to directly address the
- FDA Approves Twice-Daily Dosing of Vuity for Adults with Presbyopiahttps://modernod.com/news/fda-approves-twice-daily-dosing-of-vuity-for-adults-with-presbyopia/2481502/The FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, according to AbbVie, the parent company of Allergan. A second dose (one additional drop in each eye) may be administered 3-6 hours after the fi